Screener
Ironwood Pharmaceuticals IRWD Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from employee stock purchase plan | 303 | 94 |
| Repayment of 2026 Convertible Notes | (200,000) | — |
| Net cash provided by (used in) financing activities | (199,697) | 94 |
| Effect of exchange rate changes on cash and cash equivalents | (29) | (654) |
| Net increase (decrease) in cash and cash equivalents | (136,329) | 4,293 |
| Cash and cash equivalents, beginning of period | 215,456 | 88,559 |
| Cash and cash equivalents, end of period | $79,127 | $92,852 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's net change in cash?
- Ironwood Pharmaceuticals (IRWD) reported net change in cash of -$141.34M in Q2 2026.
- What is the long-term trend for Ironwood Pharmaceuticals's net change in cash?
- Over 2 years (2021 to 2023), Ironwood Pharmaceuticals's net change in cash has grown at a 48.4% compound annual growth rate (CAGR), from $257.08M to -$565.78M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Ironwood Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude